Linaclotide

Type: Keyphrase
Name: Linaclotide
First reported Apr 15 2014 - Updated Apr 15 2014 - 1 reports

Is Now The Time To Buy Ironwood Pharmaceuticals?

By Kevin Quon :Pharmaceutical companies with recently commercialized products can often be promising investment opportunities. One such company that has recently launched a new treatment option is Ironwood Pharmaceuticals ( IRWD ) . Ironwood Pharmaceuticals ... [Published BioPortfolio - Apr 15 2014]
First reported Apr 10 2014 - Updated Apr 11 2014 - 5 reports

Ironwood Pharmaceuticals and Forest Laboratories announce new LINZESS campaign

US-based medicinal company Ironwood Pharmaceuticals (NasdaqGS:IRWD) and US-based Forest Laboratories (NYSE:FRX) launched on Thursday a new direct-to-consumer (DTC) patient awareness campaign for LINZESS (linaclotide) for treating adults with irritable ... [Published Individual.com - Apr 11 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Ironwood Pharmaceuticals : to Host First Quarter 2014 Investor Update Call

IronwoodPharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will hostits first quarter 2014 investor update conference call and webcast at8:30 a.m. Eastern Time on Tuesday, April 29, 2014. Individualsinterested in participating in the call should ... [Published 4 Traders - Apr 08 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

AstraZenaca: Profit Prescription

More from Mark Skousen The Maxims of Wall Street Where Has All the Silver Gone? Is the Market Due for a Correction? Learn About the Expert Based in London, our latest featured stock idea is one of the world’s leading pharmaceutical companies, operating ... [Published MoneyShow.com - Mar 31 2014]
First reported Mar 26 2014 - Updated Mar 26 2014 - 1 reports

New treatment for IBS(1)

25 2014.NHS patients in Wales will now have access to a first-in-class pharmaceutical treatment for irritable bowel syndrome with constipation (IBS-C). The positive recommendation by the All Wales Medicines Strategy Group (AWMSG) of  Constella (linaclotide) ... [Published GM Journal - Mar 26 2014]
First reported Mar 25 2014 - Updated Mar 26 2014 - 1 reports

Human medicines European public assessment report (EPAR): Constella, linaclotide, Revision: 6, Authorised

Entities: Constella, Linaclotide
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

What is irritable bowel syndrome?

Irritable bowel syndrome is a functional disorder of the gastrointestinal system. It is marked by changes in how the gastrointestinal tract functions. However, it is not a disease. Rather, it is a collection of symptoms that happen together.Abdominal ... [Published Orthopedics Today - Mar 21 2014]
First reported Mar 18 2014 - Updated Mar 18 2014 - 1 reports

Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-37...

Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux DiseaseMar. 18, 2014 Business Editors/Health/Medical WritersCAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 18, 2014--Ironwood Pharmaceuticals, Inc. ... [Published Finwin - Mar 18 2014]
First reported Feb 10 2014 - Updated Feb 10 2014 - 11 reports

Ironwood Receives Notice of Allowance for Methods of Use Formulation Patent Expected to Extend LINZESS® Patent Protection Through 2031

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS® (linaclotide) ... [Published EON Environment - Feb 10 2014]
First reported Jan 08 2014 - Updated Jan 09 2014 - 1 reports

The Deal: Forest Widens Business, Pays $2.9 Billion for Aptalis

NEW YORK (TheStreet) -- Forest Laboratories Inc.  is shoring up its gastrointestinal business in the U.S. and gaining a cystic fibrosis business in Europe with the acquisition of private specialty drug company Aptalis Holdings Inc. Forest said Wednesday ... [Published The Street Latest - Jan 08 2014]

Quotes

In January 2014, Ironwood Pharmaceuticals reduced its employee workforce by 10% in order to "align its workforce with its strategy to grow a leading gastrointestinal therapeutics company." In doing so, the company cut approximately 50 jobs...
...BCh., senior vice president, clinical development of Ironwood. "Refractory GERD is a significant unmet need among those suffering with gastrointestinal disorders, and we are investigating IW-3718 to assess whether it may help prevent bile acid reflux and provide relief for patients."
"Aptalis is an excellent strategic fit with Forest," Brent Saunders, CEO and president of Forest, said in a conference call with investors. "Adding Aptalis products will diversify our offerings in key therapeutic areas" such as gastrointestinal in the U S and cystic fibrosis therapies in Europe and Canada

More Content

All (26) | News (11) | Reports (0) | Blogs (15) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
Is Now The Time To Buy Ironwood Pharmaceuticals? [Published BioPortfolio - Apr 15 2014]
Is Now The Time To Buy Ironwood Pharmaceuticals? [Published Seeking Alpha - Apr 15 2014]
Ironwood Pharmaceuticals and Forest Laboratorie... [Published Individual.com - Apr 11 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Investor's Business Daily - Apr 10 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire Photo/Multimedia News - Apr 10 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire Health News - Apr 10 2014]
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire News with Multimedia - Apr 10 2014]
Ironwood Pharmaceuticals : to Host First Quarte... [Published 4 Traders - Apr 08 2014]
AstraZenaca: Profit Prescription [Published MoneyShow.com - Mar 31 2014]
New treatment for IBS(1) [Published GM Journal - Mar 26 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 25 2014]
What is irritable bowel syndrome? [Published Orthopedics Today - Mar 21 2014]
Ironwood Pharmaceuticals Initiates Phase II Cli... [Published Finwin - Mar 18 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Environment - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Transportation - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Business - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Consumer - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Retail - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Manufacturing - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Energy - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Communications - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON: Enhanced Online News - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Science - Feb 10 2014]
Ironwood Receives Notice of Allowance for Metho... [Published Business Wire Health News - Feb 10 2014]
The Deal: Forest Widens Business, Pays $2.9 Bil... [Published The Street Latest - Jan 08 2014]
Ironwood, AstraZeneca begin phase III trial in ... [Published PharmaBiz - Sep 12 2013]
1
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire Photo/Multimedia News - Apr 10 2014]
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS® (linaclotide), ...
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire Health News - Apr 10 2014]
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS® (linaclotide), ...
Ironwood and Forest Launch New Direct-to-Consum... [Published Business Wire News with Multimedia - Apr 10 2014]
CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) and Forest Laboratories, Inc. (NYSE:FRX) announced today that they have commenced a new direct-to-consumer (DTC) patient awareness campaign for LINZESS® (linaclotide), ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - Mar 25 2014]
Ironwood Receives Notice of Allowance for Metho... [Published EON Environment - Feb 10 2014]
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a patent application covering methods of using LINZESS® (linaclotide) ...
1 2 3
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.